Clinical trials: DENGUE
Dengue Fever
Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants
The purpose of this study is to assess the humoral immune responses to three different dose schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) administered subcutaneously in healthy participants between 2 and <18…
- Trial name
- NCT02302066
- Testing
- Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
- Where
- 3 sites in Dominican Republic, Panama and 1 more
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
International Research Consortium on Dengue Risk Assessment, Management, and Surveillance
Improvements in diagnosis of dengue fever and prediction of which patients will get more severe disease are urgently needed to improve the treatment of patients with dengue.
- Trial name
- IDAMS (NCT01550016)
- Testing
- Observation
- Where
- 9 sites in Bangladesh, Brazil and 6 more
- Volunteers
- 7,411 people
- Sponsor
- University of Heidelberg Medical Center
Knowledge, Attitudes, Practice
Effectiveness of iDEAL in Improving the Knowledge, Attitude, Practice, Environmental Cleanliness Index and Dengue Index
Background Dengue is a mosquito-borne viral disease caused by four distinct but closely related dengue virus (DENV). The incidence of dengue has grown dramatically worldwide in recent decades, with cases reported to WHO increased…
- Trial name
- iDEAL (NCT05863026)
- Testing
- THEORY BASED INTEGRATED DENGUE EDUCATION AND LEARNING MODULE (iDEAL)
- Where
- Malaysia
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Universiti Putra Malaysia
Dengue Vaccines
Retrospective Analysis of the Second Year of Safety Surveillance of the Qdenga® (TAK-003) Vaccine in Private Vaccination Centers, Including a Sub-analysis of Safety in Adults Over 60 Years of Age
The TAK-003 vaccine, Qdenga, developed by Takeda, was approved by ANMAT in April 2023 and has been available in Argentina since November 2023 for individuals aged 4 years and older, with no upper age limit.
- Trial name
- NCT07812142
- Testing
- Tak-003
- Where
- Argentina
- Volunteers
- 94,526 people, healthy volunteers welcome
- Sponsor
- Fundación Vacunar
Dengue, Pregnancy Preterm
Materno-fetal Consequences of Symptomatic Dengue in Pregnant Wowen in French Guiana
Symptomatic dengue virus infection in pregnant women could affect the mother, fetus and the newborn at birth. The risks of postpartum hemorrhage, prematurity and low birth weight are increased in dengue fever.
- Conditions
- Dengue, Pregnancy Preterm, Women, Fever
- Trial name
- CMFdeng (NCT04989673)
- Testing
- Biological sampling and collection (serum), Biological sampling and collection (placenta), Questionnaire
- Where
- French Guiana
- Volunteers
- 628 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier de Cayenne
Healthy
A Study to Evaluate V181 Dengue Vaccine in Healthy Participants 2 to 17 Years of Age (V181-005/MOBILIZE-1)
The purpose of this study is to demonstrate that V181 is safe and well tolerated, elicits an immune response, and reduces the frequency of virologically confirmed dengue (VCD) of any severity, due to any of the 4 dengue…
- Trial name
- NCT07013487
- Testing
- V181
- Where
- 41 sites in Indonesia, Malaysia and 5 more
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Dengue Fever
Investigation of the Immuno-regulation and Viral Hepatitis Among Patients With or After Dengue Fever Infection
The study will collect the blood samples from 350 healthy persons and 350 persons infected with dengue fever.
- Trial name
- NCT00688389
- Testing
- case/control
- Where
- Taiwan
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue Fever
Factors Associated With Poor Dengue Outcomes in Malaysia
This study aims to analyse the results of national data collected by the e-Dengue Information System in order to determine the factors associated with disease outcomes in all patients registered from January 2013 to December 2014.
- Trial name
- NCT02510690
- Where
- Malaysia
- Volunteers
- 20,000 people
- Sponsor
- Clinical Research Centre, Malaysia
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
The aim of the study was to assess and describe the booster effect of a CYD dengue vaccine dose administered 4 to 5 years after the completion of a 3-dose vaccination schedule.
- Trial name
- NCT02623725
- Testing
- CYD Dengue Vaccine (5-dose formulation)
- Where
- 5 sites in Brazil, Colombia and 3 more
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acquired Bleeding Disorder, Dengue Haemorrhagic Fever
Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
This trial is conducted in Asia. The aim of this is to investigate the efficacy and safety of activated recombinant human factor VII (rFVIIa) in achieving haemostasis in patients with Dengue haemorrhagic fever (DHF).
- Trial name
- NCT01601613
- Testing
- activated recombinant human factor VII
- Where
- 9 sites in Malaysia, Philippines and 1 more
- Volunteers
- 28 people
- Sponsor
- Novo Nordisk A/S
Mass Screening
Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol
The purpose of the study is to screen blood donors for the presence of NS1 antigen of the dengue virus at the American Red Cross in Puerto Rico region (and Monroe County, Florida) using the Platelia Dengue NS1 Ag enzyme…
- Trial name
- NCT01226173
- Testing
- Bio-Rad Platelia Dengue NS1 Ag test
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 182,353 people, healthy volunteers welcome
- Sponsor
- Bio-Rad Laboratories
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01656174
- Testing
- Procleix Dengue Virus Assay
- Where
- 2 sites in United States
- Volunteers
- 35,035 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Dengue
Follow-up the Health Condition , Investigation of the Immuno-regulation , and the Study for Interaction of Viral Hepatitis--- Among Patients With or After Dengue Fever Infection
Originally test host's to understand the tracking healthily and immune change of the dengue fever in Taiwan. Blood drawing 20 c.c for liver examination, kidney and other biochemical function, analyze host immunity adjusts and…
- Trial name
- NCT00629356
- Testing
- dengue fever
- Where
- Taiwan
- Volunteers
- healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Dengue
Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS
The objective of this study is to test individual donor samples (IDSs) with the investigational Dengue Assay on the TIGRIS System and to further characterize the Dengue Assay in the clinical setting.
- Trial name
- NCT01702272
- Testing
- Procleix Dengue Virus Assay
- Where
- United States
- Volunteers
- 150,000 people, healthy volunteers welcome
- Sponsor
- Gen-Probe, Incorporated
Dengue Virus, Dengue Fever
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
The aim of the trial was to evaluate the use of a tetravalent vaccine, CYD dengue vaccine, against dengue disease. Primary Objectives: To describe the humoral immune response to dengue before and after each vaccination with…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00788151
- Testing
- CYD Dengue Vaccine Serotypes 1, 2, 3, and 4, Pneumococcal polysaccharide vaccine
- Where
- Peru
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia
The purpose of this study was to evaluate the safety and immunogenicity of Phase III lots of the CYD dengue vaccine in a pediatric population in Malaysia.
- Trial name
- NCT01254422
- Testing
- Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus
- Where
- 4 sites in Malaysia
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi
Dengue Fever
A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
To assess the safety, reactogenicity and immunogenicity of two doses of the dengue vaccine in Flavi-virus antibody-naive children between 6 and 9 years of age.
- Trial name
- NCT00384670
- Testing
- Dengue Vaccine Formulation 17, Licensed Japanese Encephalitis (JE) Vaccine
- Where
- Thailand
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria Fever, Zika
Xpert® Tropical Fever Test on GeneXpert® Edge X System
This is a multi-site, observational, cross-sectional clinical study that includes geographically diverse sites within and outside the United States.
- Conditions
- Malaria Fever, Zika, Dengue Fever, Leptospirosis
- Trial name
- NCT07520279
- Testing
- Xpert Tropical Fever test
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Cepheid
Dengue Virus, Dengue Fever
Efficacy and Safety of Dengue Vaccine in Healthy Children
The primary objective of the study was to assess the efficacy of CYD dengue vaccine after three injections in preventing symptomatic virologically-confirmed dengue (VCD) cases, regardless of the severity, due to any of the four…
- Conditions
- Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever, Dengue Diseases
- Trial name
- NCT00842530
- Testing
- CYD Dengue Vaccine, Inactivated rabies virus vaccine
- Where
- Thailand
- Volunteers
- 4,002 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Aedes-borne Diseases, Dengue
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
The objective of this trial is evaluate the efficacy of Targeted Indoor Residual Spraying (TIRS) in preventing symptomatic disease caused by Aedes-borne diseases (ABDs) in children 2 to 15 years of age in the city of Merida…
- Conditions
- Aedes-borne Diseases, Dengue, Chikungunya, Zika
- Trial name
- NCT04343521
- Testing
- Targeted Indoor Residual Spraying (TIRS)
- Where
- Mexico
- Volunteers
- 4,461 people
- Sponsor
- Emory University